ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 445,69
2,24%
Dow Jones
42 706,56
-0,06%
DAX
20 216,19
1,54%
Brent Oil
76,115
-0,51%
Bitcoin
102 208,10
3,94%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. L'Europe
  5. EU
  6. Pharming Group NV (PHARM)

  7. Pharming Group NV (PHARM) Actualités

PHARM

Pharming Group NV (PHARM)

Pharming Group NV
De:
Trier par:
 Showing the most relevant articles for your search:EU:PHARM
DateHeureSourceTitreSymboleSociété
15/12/202419h45GlobeNewswire Inc.Pharming announces public cash offer to the shareholders of Abliva ABEU:PHARMPharming Group NV
11/12/202407h00GlobeNewswire Inc.Pharming announces positive topline data in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
05/11/202408h00GlobeNewswire Inc.Pharming Group to participate in November investor conferenceEU:PHARMPharming Group NV
24/10/202407h00GlobeNewswire Inc.Pharming Group reports third quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
10/10/202408h00GlobeNewswire Inc.Pharming Group to report third quarter 2024 financial results on October 24EU:PHARMPharming Group NV
10/10/202407h00GlobeNewswire Inc.Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulationEU:PHARMPharming Group NV
26/09/202407h00GlobeNewswire Inc.Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)EU:PHARMPharming Group NV
04/09/202407h00GlobeNewswire Inc.Pharming Group to participate in September investor conferencesEU:PHARMPharming Group NV
01/08/202407h00GlobeNewswire Inc.Pharming Group reports second quarter and first half 2024 financial results and provides business updateEU:PHARMPharming Group NV
18/07/202408h00GlobeNewswire Inc.Pharming Group to report second quarter and first half 2024 financial results on August 1EU:PHARMPharming Group NV
03/06/202408h00GlobeNewswire Inc.Pharming Group to participate in June investor conferencesEU:PHARMPharming Group NV
30/05/202422h44GlobeNewswire Inc.Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European UnionEU:PHARMPharming Group NV
21/05/202417h30GlobeNewswire Inc.Pharming Group reports on results of the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
20/05/202408h00GlobeNewswire Inc.Pharming Group to participate in May investor conferenceEU:PHARMPharming Group NV
15/05/202407h00GlobeNewswire Inc.Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/05/202407h00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
24/04/202408h00GlobeNewswire Inc.Pharming Group to report first quarter 2024 financial results on May 8EU:PHARMPharming Group NV
24/04/202407h00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
19/04/202418h43GlobeNewswire Inc.Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
18/04/202415h04GlobeNewswire Inc.Pharming Group announces the placement of €100 million convertible bonds due 2029EU:PHARMPharming Group NV
18/04/202408h00GlobeNewswire Inc.Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/04/202407h00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
04/04/202408h30GlobeNewswire Inc.Pharming Group announces the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
04/04/202407h00GlobeNewswire Inc.Pharming Group announces the filing of its 2023 Annual Report and Form 20-FEU:PHARMPharming Group NV
03/04/202408h00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
14/03/202407h00GlobeNewswire Inc.Pharming Group reports fourth quarter and full year 2023 financial resultsEU:PHARMPharming Group NV
29/02/202408h00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
08/02/202408h00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/01/202407h00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
13/12/202307h00GlobeNewswire Inc.Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)EU:PHARMPharming Group NV
 Showing the most relevant articles for your search:EU:PHARM

Dernières Valeurs Consultées

COIN
SOLUSD
Solana
EU
RNO
Renault
COIN
ADAUSD
Cardano
NASDAQ
AMZN
Amazon.com
EU
ORA
Orange
NASDAQ
GOOGL
Alphabet
EU
ML
Michelin
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
EU
BN
Danone
NASDAQ
MSFT
Microsoft
NASDAQ
NVDA
NVIDIA
EU
LR
Legrand
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés